ClinicalTrials.gg
WithdrawnNCT04354727Updated Jul 12, 2022

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

A Phase 1/2 interventional study of APG-1252 and Ruxolitinib in Myelofibrosis, sponsored by Ascentage Pharma Group Inc.. Withdrawn at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-12.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 1/2, Interventional, and Treatment

How we know

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.

Enrollment
380th of 388
0 · median 40
Started
2020
with 14 others
Phase 1/2
50 of 454
11 open now
Registered
352nd of 454
by date

Among the 454 studies in Primary Myelofibrosis with a site in United States, this one is the 380th largest by enrollment of the 388 interventional ones that give a count, is one of 15 that started in 2020, is one of 50 in phase 1/2, and was the 352nd registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

70 of the 454 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Primary Myelofibrosis with a site in United States, or all of them as a file.
02

Study summary

The study is a designed to evaluate safety and activity of APG-1252 when administered as monotherapy and in combination with ruxolitinib in previously ruxolitinib treated myelofibrosis patients.

Read the detailed description

Part 1 will evaluate safety of APG-1252 monotherapy using a 3+3 dose escalation study design. The starting dose of APG-1252 monotherapy will be 160 mg administered as an intravenous injection over 30 minutes once weekly in a 28-day cycle. If the APG-1252 at 160 mg is tolerated (0/3 and ≤ 1/6 DLTs), dose escalation to 240 mg will be evaluated and declared as recommended phase 2 dose (RP2D) if tolerated. No doses higher than 240 mg once per week will be explored. If the 160 mg once weekly dose schedule is not tolerated (≥ 2/3 or ≥ 2/6 DLTs) de-escalation to 80 mg once weekly dose will be explored. No doses under 80 mg of APG-1252 will be explored as monotherapy. Maximum tolerated dose (MTD)/RP2D is defined as the highest dose with ≤ 1/6 patients with dose limiting toxicities. A maximum of 6 patients will be treated at the APG-1252 monotherapy dose level to further characterize safety. Part 2 will commence once APG-1252 monotherapy MTD/RP2D is determined following review of safety and tolerability of APG-1252 monotherapy and discussion between sponsor and investigators. In Part 2, APG-1252 will be tested in combination with ruxolitinib. Part 2 will evaluate tolerability and clinical benefit of the combination APG-1252 plus ruxolitinib using a 3+3 dose escalation design. Patients starting APG-1252 treatment as an addition to ruxolitinib should have been on ruxolitinib daily dose for at least 5 days at the same dose. If they were on fedratinib they should discontinue fedratinib and switch to ruxolitinib for at least 5 days before the addition of APG-1252. The starting dose of APG-1252 in Part 2, will be one dose level lower than the MTD of APG-1252 as monotherapy (i.e, at 80 mg if MTD is 160 and 160 mg if MTD is 240 mg) and will be increased to a maximum of 240 mg once per week, added to ruxolitinib. Once the MTD/RP2D of combination arm is determined, additional patients up to a maximum of 15 will be treated at the RP2D to further evaluate safety and clinical benefit.

03

Conditions studied

  • Myelofibrosis

Keywords

  • JAK2 wild type
  • JAK2V617F mutation
  • Thrombocythemia
  • Polycythemia vera
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed myelofibrosis requiring therapy including:

    1. Either primary or post essential thrombocythemia/polycythemia vera
    2. Have intermediate-2 or high-risk myelofibrosis by International Prognostic Scoring System (IPSS) scoring system
    3. If intermediate-1 myelofibrosis must have palpable splenomegaly ≥ 5 cm below left costal margin
    4. Either in chronic (CP) or accelerated phase (AP)
    5. Patients can be either JAK2 wild type or JAK2V617F mutated
  • Patients must be ineligible or unwilling to undergo a stem cell transplantation or receive any other approved standard of care at the time of study entry
  • Patients have been previously treated with a JAK inhibitor (JAKi) and are intolerant, resistant, or lost response to the JAKi ruxolitinib or fedratinib, or had sub-optimal response to ruxolitinib. Patients in Part 1 will be those ineligible to receive ruxolitinib and other approved standard of care. (Patients will be defined as having received sub-optimal response to ruxolitinib if, they achieved inadequate response to ruxolitinib based therapy after 6 months of treatment, or had been on a stable dose of ruxolitinib based therapy for \< 24 weeks and had shown initial response but in opinion of investigators were unlikely to benefit from continuing dose and schedule of ruxolitinib).
  • (ECOG) performance score of 0-2
  • Adequate bone marrow function:

    1. (ANC) ≥ 0.750 X 10˄9/L
    2. (Hb) ≥ 9.0 g/dL
    3. count ≥ 50 X 10˄9/L (independent of transfusion within14 days of first dose)
    4. (INR), prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5 X (ULN) unless the subject is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
  • Adequate renal and liver function as indicated by:

    1. Direct \< 2.0 mg/dL (unless Gilbert's syndrome and evidence of hemolysis)
    2. Serum creatinine \< 1.5 mg/dL, if >1.5 mg/dL, must be ≥ 50 mL/min
    3. (AST) and/or alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (unless considered to be related to myelofibrosis or patient has known history of Gilberts)
    4. Alkaline phosphatase \< 2.5 x ULN
    5. Albumin ≥ 2.5g/dl
  • Willingness to use method that is deemed effective by the investigator by female patients of child bearing potential ( women amenorrhea for at least 12 months to be considered of non-) and males with partners of child bearing potential, throughout the treatment period and for at least three months following the last dose of study drug
  • Ability to understand and willingness to sign a written form
  • Willingness and ability to comply with study procedures and follow-up examination

Exclusion criteria

Exclusion Criteria:

  • Received standard or experimental therapy within 14 days or 5 half-lives (whichever is greater) before starting study therapy
  • Previously received other B-cell lymphoma-extra large (Bcl-xL) inhibitors
  • Receiving concomitant anticancer therapy, except hormonal therapy and patients on ruxolitinib
  • Disease associated with myelofibrosis such as carcinoma, lymphoma, myelodysplasia, hairy cell leukemia, mast cell disease or acute leukemia
  • Radiation within 14 days of study entry, thoracic radiation within 28 days of study entry
  • Has gastrointestinal conditions that could affect the absorption of oral medication
  • Has known active central nervous system (CNS) involvements
  • Lack of toxicity recovery from previous therapy ≤ grade 1 or baseline (except alopecia, , neutropenia and thrombocytopenia)
  • Use of therapeutic anticoagulants
  • Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry
  • Unstable angina, or other significant cardiac condition including:

    1. Unstable arrhythmia on treatment including permanent cardiac pacemaker
    2. History of symptomatic congestive heart failure ( [NYHA] Class III or IV)
    3. History of myocardial infarction within 6 months of enrollment
    4. Current unstable angina
    5. Family history of long syndrome or corrected QT interval (QTc) (Fridericia or Bazett) > 480 msec
  • Active infection requiring systemic antibiotic/ antifungal medication, known clinically active or C infection, or on antiretroviral therapy for disease
  • Uncontrolled concurrent illness including, but not limited to: psychiatric illness/social situations that would limit compliance with the study requirements or any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study
  • Women who are pregnant, breast feeding or women of (WOCBP) not using an effective method of . WOCBP are sexually active mature women who have not undergone a hysterectomy or who have not been achieved for at least 12 consecutive months. WOCBP must have a negative serum pregnancy test with 72 hours of receiving the first dose of study medication
  • Male patients whose sexual partners are WOCBP not using effective birth control
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    APG-1252

    Drug: APG-1252

  • Experimental
    APG-1252 + Ruxolitinib

    Drug: APG-1252 · Drug: Ruxolitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) rate at each dose level

    DLT will be assessed within the first 28-day cycle of study treatment via CTCAE version 5.0

    Time frame: 28 days

  2. Spleen Volume Measurement Reduction

    At least a 35% reduction in spleen volume or ≥ 50% reduction in myelofibrosis related total symptom score (TSS)

    Time frame: 24 weeks

07

Study locations

2 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2020; primary completion for Dec 2022, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2020
First posted
Apr 21, 2020
StartEst.
Dec 15, 2020
Primary completionEst.
Dec 15, 2022
CompletionEst.
Jun 15, 2023
Last update
Jul 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04354727
Responsible party
Sponsor
First posted
Apr 21, 2020
Start date
Dec 15, 2020 (estimated)
Primary completion
Dec 15, 2022 (estimated)
Completion
Jun 15, 2023 (estimated)
Last update
Jul 12, 2022

Study contacts

Yifan Zhai, MD, PhD
study chair · Ascentage Pharma Group Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelcitoclax

Start the discussion